Menopause Comfort Program — Topical + Oral Pairing on One Documentation Chain

The problem this playbook solves: the menopause shelf splits between hormone therapeutics and vague herbal blends — a documented, gentle, stage-specific daily ritual is the missing middle.

01 · The problem

The menopause shelf forces a false choice: hormone therapeutics (clinical, not a shelf product) or herbal blends (vague actives, thinner files every year). Women 45–55 running real wellness routines have no documented, gentle, daily-ritual option a brand can stand behind without overclaiming. The trust bar is the highest in consumer wellness — and the documentation gap is why.

02 · Scientific rationale

The design answer is pairing: a topical gentle mist (rose-derived plant EV fractions, soft-care formula) for daily comfort, paired with a stage-specific oral formula on the OralBio base — one documentation chain across both. Claims stay at comfort and ritual level; Functional claims follow each market's own filing — EU permitted-claims lists, US structure/function discipline. The program tracks routine adherence; the 30-day pairing card exists to keep both SKUs in one ritual.

03 · Program documentation

Protocol documentation for this program family is maintained in TONGNIAN's internal files — network-clinic protocol series and anonymized case records where applicable [5]. Partner access under NDA; the evidence hierarchy stays explicit — published reviews first, internal observational programs second, case documentation third. [6]

Method anchors: [1] EV biology and cargo [2] MISEV2018 characterization [3] category evidence (review or registered study) [4] formulation and handling guidance [5] national measurement guideline (2026 No. 17) [6] internal protocol and case documentation.

04 · Product architecture

05 · Process & QC

EV material runs on the fully enclosed 0.5–5 L micro-batch line — closed-tubing culture, scheduled harvest, tangential-flow separation and concentration, sterile filtration — with low-shear handling qualified at process validation [4]. QC panel design follows MISEV2018 [2] and the national measurement guideline (2026 No. 17; TONGNIAN is a drafting organization) [3].

Fig. 1 — The pairing map: topical step + oral step, one program card.

06 · Regulatory pathway: EU & US first

US: dietary-supplement route for the oral pairing (DSHEA, structure/function-style discipline); EU: food-supplement framework with permitted-claims lists. Topical mist: cosmetic track both markets. China market entry later follows the health-food route on the same base — additional market.

07 · Expected outcomes

• Adherence-first design: the pairing card turns two SKUs into one ritual.
• Trust by documentation: COA and characterization baseline on both components.
• No hormone or therapeutic claims — the shelf position is the legal-safe middle.

Wording stays inside each destination market's rules; batch measurement does the persuading.

08 · Commercial framework

Sample kits in 3–5 days; pilot from 500 units; production from 2,000 units; standard lead 15 workdays — all indicative, quoted per request. White-label and program naming run through the OBM program.

Request a quote · Line fact-sheet

References

1. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.
2. Ávila-Gálvez MÁ, et al. Oral delivery of ellagic acid encapsulated in milk exosomes. Mol Nutr Food Res. 2026.
3. Guideline for Exosome Particle Size and Concentration Measurement (2026 No. 17), national standard — TONGNIAN, drafting organization.
4. TONGNIAN network clinics. Anonymized internal protocol and case documentation (partner access under NDA).